Your session is about to expire
← Back to Search
Behavioral Intervention
Contingency Management for Methamphetamine Addiction (PRISE Trial)
N/A
Waitlist Available
Led By David C Hodgins, PhD
Research Sponsored by University of Calgary
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to post-intervention week 12 and from week 12 to week 15 (3-month follow-up), week 18 (6-month follow-up), and week 24 (12-month follow-up).
Awards & highlights
PRISE Trial Summary
This trial will help to understand if an evidence-based intervention called contingency management is effective in treating methamphetamine addiction in Alberta.
Eligible Conditions
- Substance Abuse
- Contingency Management
- Substance Use
- Methamphetamine Addiction
- Substance Use Disorder
- Adult
- Methamphetamine
- Human
- Methamphetamine Abuse
PRISE Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline to post-intervention week 12 and from week 12 to week 15 (3-month follow-up), week 18 (6-month follow-up), and week 24 (12-month follow-up).
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to post-intervention week 12 and from week 12 to week 15 (3-month follow-up), week 18 (6-month follow-up), and week 24 (12-month follow-up).
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Differences in Treatment Retention from Baseline to Post-Intervention at Week 12
Secondary outcome measures
Largest Number of Units Consumed of Other Quantifiable Licit and Illicit Substances in One Day Measured Using the Timeline Followback (TLFB) Questionnaire
Longest Consecutive Days Absent from Scheduled Treatment from Baseline to Post-Intervention at Week 12
Longest Consecutive Days Abstinent from Other Licit and Illicit Substances Measured Using the Timeline Followback (TLFB) Questionnaire
+11 moreOther outcome measures
Changes in Quality of Life Measured Using the 26-item World Health Organization (WHO) Quality of Life-BREF (WHOQOL-BREF)
Differences in Costs Between Contingency Management and Treatment-As-Usual
Differences in Health Service Use Between Contingency Management and Treatment-As-Usual
+2 morePRISE Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Contingency management for treatment attendanceExperimental Treatment1 Intervention
Participants who receive contingency management in addition to their usual care (treatment-as-usual). These participants are in the 12-week contingency management program which provides incentives for their treatment attendance.
Group II: Treatment-as-usualActive Control1 Intervention
Participants who solely receive their usual care (treatment-as-usual) and do not receive contingency management.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Contingency management
2006
Completed Phase 4
~960
Find a Location
Who is running the clinical trial?
University of CalgaryLead Sponsor
792 Previous Clinical Trials
869,066 Total Patients Enrolled
Alberta Health servicesOTHER
158 Previous Clinical Trials
649,578 Total Patients Enrolled
David C Hodgins, PhDPrincipal InvestigatorUniversity of Calgary
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You are seeking treatment for methamphetamine use or substance use issues other than methamphetamine use.You are willing to answer questionnaires every week during the 12-week treatment period and at 3, 6, and 12 months after the treatment period.You agree to attend follow-up appointments either in-person or virtually after the 12-week study period at 3, 6, and 12 months.You have reported methamphetamine use or substance use other than methamphetamine use within 3 months prior to study entry.You are willing to participate in the 12-week intervention in-person or virtually at least once weekly.You must be 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Treatment-as-usual
- Group 2: Contingency management for treatment attendance
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies for this trial that a patient could take advantage of?
"Contrary to expectations, clinicaltrials.gov confirms that this trial is not actively recruiting patients at the current moment in time despite having been initially posted on January 25th 2021 and edited as recently as November 12th 2022. Yet there are 420 other trials which are currently enrolling participants."
Answered by AI
Who else is applying?
What state do they live in?
New Jersey
How old are they?
18 - 65
What site did they apply to?
Adult Addiction Services in Alberta Health Services
What portion of applicants met pre-screening criteria?
Met criteria
How responsive is this trial?
Typically responds via
Email
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger